antimycobacterial

antimycobacterial (Zambon) refers to an undisclosed antimicrobial drug candidate currently in the preclinical stage of development by Zambon. Targeted at mycobacterial infections, particularly non-tuberculous mycobacterial (NTM) lung disease, the program is part of Zambon's specialty respiratory portfolio. The drug is being developed as an inhaled therapy to provide high local concentrations of the antibiotic directly in the lungs while minimizing systemic side effects. The program was likely acquired or expanded through Zambon's acquisition of Breath Therapeutics, where it was designated as BOD-003. As of 2024, the specific chemical identity and molecular mechanism of the candidate have not been publicly revealed.